ScholarWorks@SUNGKYUNKWAN UNIVERSITY: JEON, SEONG SOO

Detailed Information

JEON, SEONG SOO (전성수)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prostate cancer:23||Renal cell carcinoma:13||Prostatectomy:12||Prostatic neoplasms:11||Nephrectomy:11||prostate cancer:11||Magnetic resonance imaging:7||Biopsy:7||Survival:6||renal cell carcinoma:6||Robotics:6||prostatic neoplasms:5||Prostate:5||Partial nephrectomy:5||Prostatespecific antigen:5||Laparoscopy:5||Prostate neoplasms:5||Prostatic Neoplasms:4||Prostate biopsy:4||radical prostatectomy:4||Prostatic neoplasm:4||Diagnosis:4||nephrectomy:4||Docetaxel:4||Gleason score:4||bladder cancer:4||magnetic resonance imaging:3||Carcinoma:3||biochemical recurrence:3||Active surveillance:3||Oncologic outcomes:3||prognosis:3||carcinoma, renal cell:3||prostatespecific antigen:3||prostatectomy:3||Focal therapy:3||Outcome:3||MRI:3||Kidney:3||recurrence:3||Chemotherapy:3||Treatment outcome:3||Upper tract urothelial carcinoma:3||Ureteral obstruction:3||kidney:3||Ureteroscopy:3||Hemiablation:3||Urothelial carcinoma:3||nephroureterectomy:2||Renal Cell:2||Nephroureterectomy:2||Biomarkers:2||curcumin:2||cystectomy:2||Prognosticator:2||Risk:2||urothelial carcinoma:2||Targeted biopsy:2||Computed tomography:2||Recurrence:2||renal cell:2||Repeat biopsy:2||diagnosis:2||mortality:2||Doctor&apos:2||risk:2||Transperineal:2||Biweekly:2||Transrectal ultrasonography:2||Transrectal ultrasound:2||Radical Prostatectomy:2||Renal function:2||s Answer:2||Bladder cancer:2||Radical nephrectomy:2||Pathology:2||Radical prostatectomy:2||glomerular filtration rate:2||Tyrosine kinase inhibitor:2||Metastatic renal cell carcinoma:2||hypertrophy:2||survival:2||Radiofrequency ablation:2||Ultrasound:2||metastatic renal cell carcinoma:2||Urinary bladder neoplasms:2||Chronic kidney disease:2||Operative surgical procedures:2||carcinoma:2||predictor:2||prostate health index:2||Minimally invasive:2||Artificial intelligence:2||partial nephrectomy:2||Adjuvant chemotherapy:2||Surgical procedure:2||immunotherapy:2||prostatespecific antigen density:2||Computerized tomography:2||Hypertrophy:2||prostatic neoplasm:2||Robotic surgical procedures:2||watchful waiting:2||Metachronous:1||Metastasis:1||Miles’ operation:1||Minimally Invasive Surgical Procedures:1||Minimally invasive surgical procedures:1||Monoclonal antibody:1||Mortality:1||Multidetector computed tomography:1||Mutation:1||Neoplasm:1||Neoplasm metastasis:1||Nephrometry score:1||Nephronsparing surgery:1||Nomogram:1||Observation:1||Occupational sunlight exposure:1||Oncological outcome:1||Onion (Allium cepa) peel extract:1||Organ size:1||Osteosarcoma:1||Outcomes:1||PIRADS:1||PROMISE CLIP project:1||PROMISE CLIP registry:1||PTEN:1||Pathology data:1||Patient selection:1||Pentafecta criteria:1||Pentafecta outcome:1||Percutaneous resection:1||Phosphodiesterase 5 inhibitors:1||Positive surgical margin:1||Predictive factor:1||Predictive model:1||Predictors:1||Prior biopsynegative patients:1||Prognosis:1||Prognostic factor:1||Programmed cell death 1 ligand 1:1||Propensity scorematching:1||Prospective registry:1||Prostate Biopsy:1||Prostate Cancer:1||Prostate Imaging Reporting and Data:1||Prostate Imaging Reporting and Data System (PIRADS):1||Prostate ImagingReporting and Data System:1||Prostate anterior fat pad:1||ProstateSpecific Antigen:1||Prostatespecific antigen density (PSAD):1||Prostatic Neoplasm:1||Prostatic secretory proteins:1||Psychometric properties:1||Quality:1||RCC:1||Radiation therapy:1||Radical cystectomy:1||Radical nephroureterectomy:1||Radical prostatectomy specimen:1||Radiofrequency catheter ablation:1||Radionuclide imaging:1||Radiotherapy:1||Realworld data:1||Receptor fibroblast growth factor, type 3:1||Rehabilitation:1||Renal:1||Renal cancer:1||Renal compensation:1||Renal insufficiency:1||Retropubic:1||Retrospective:1||Risk Assessment:1||Robotassisted laparoscopic partial nephrectomy:1||Robotic:1||SOX9:1||Salvage:1||Salvage therapy:1||Sarcoma:1||Sarcopenia:1||Seminal vesicle:1||Sequence analysis:1||Shear wave elastography:1||Single nucleotide polymorphism:1||Smoking:1||Stress:1||Surgery:1||Surgical:1||Synchronous:1||Synchronous metastatic renalcell carcinoma:1||System (PIRADS) score:1||Systematic biopsy:1||Systematic random biopsy:1||Systemic inflammatory response:1||TAZ:1||Technetium Tc 99m Pentetate:1||Transitional cell:1||Transitional cell carcinoma:1||Transperineal US:1||Transurethral resection of prostate:1||Treatment Outcome:1||Trend:1||Tumor volume:1||Tumour size:1||UROPDS:1||Ultrasonography:1||Upgrading:1||Upper urinary tract cancer:1||Upper urinary tract urothelial carcinoma:1||Upstaging:1||Urinary Incontinence:1||Urinary bladder:1||Urinary bladder neck obstruction:1||Urinary bladder neoplasm:1||Urothelial cell carcinoma:1||Vascular endothelial growth factor:1||Vasectomy:1||Von Hippel Lindau disease:1||Warm ischaemia:1||Watchful waiting:1||Whole genome sequencing:1||YAP1:1||Young?s modulus:1||abdominal:1||active surveillance:1||adjuvant radiotherapy:1||antiapoptosis:1||artesunate:1||artificial intelligence:1||aspartate transaminase/alanine transaminase (De Ritis) ratio:1||biomarker:1||biopsy:1||bladder:1||body mass index:1||bone metastasis:1||bone morphogenetic protein6:1||c:1||cT3:1||calculi:1||castrationresistant:1||chemoresistance:1||chroni:1||chronic kidney disease:1||cisplatin:1||clinical protocols:1||clinically insignificant prostate cancer (CIPC):1||compensation:1||complications:1||crosscultural comparison:1||cysts:1||cytokines:1||dermatomyositis:1||detection:1||disease progression:1||distant metastasis:1||diverticulum:1||docetaxel:1||drug repurposing:1||drug screening:1||early detection of cancer:1||enzalutamide resistance:1||erythrocyte sedimentation rate:1||fibrosis:1||functional and oncological outcomes:1||genitourinary system, calculi:1||health screening:1||human renal cell carcinoma:1||immune cell:1||immune checkpoint:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||immunohistochemistry:1||immunosurveillance:1||insignificant:1||intermittent androgen deprivation:1||kidney neoplasms:1||kidney, calculi:1||kidney, interventional procedure:1||laparoscopi:1||laparoscopic surgery:1||laparoscopy:1||large renal tumors:1||m:1||macrophages:1||mediator complex subunit 12:1||metastasis:1||molecular features:1||mpMRI:1||multiparametric magnetic resonance imaging:1||muscle invasive bladder cancer:1||mutation analysis:1||natural killer cell activity:1||negative predictive value:1||neoplasm metastasis:1||neoplasm metastasis, local:1||neuroendocrinelike prostate cancer cell:1||neutrophillymphocyte ratio:1||nomogram:1||obesity:1||oncologic outcome:1||oncosis:1||outcome assessment (health care):1||overall survival:1||oxidative stress:1||pain:1||patientderived xenograft:1||programmed cell deathligand 1:1||propensity score:1||propensity score matched analysis:1||propensityscore matching analysis:1||prostate health index density:1||prostate imaging and reporting and data system:1||prostate imaging reporting and data system:1||prostate neoplasms:1||prostate specific antigen:1||ALT:1||prostatic smooth muscle:1||proteintyrosine kinases:1||proteintyrosine phosphorylation:1||proteinuria:1||quality of life:1||questionnaires:1||radical cystectomy:1||radical nephrectomy:1||radiofrequency ablation:1||radiotherapy:1||random forest:1||renal function:1||renal volume:1||responsiveness:1||risk factors:1||robotassisted surgery:1||robotic:1||robotic partial nephrectomy:1||robotic surgery:1||robotics:1||salvage:1||salvage radiotherapy:1||selection bias:1||simple nephrectomy:1||sperm motility:1||staging:1||statistics:1||sunitinib:1||survival outcomes:1||syndrome:1||tomography, xray computed:1||transdifferentiation:1||transperineal prostate biopsy:1||transrectal ultrasound:1||treatment outcome:1||trend:1||tumor biomarkers:1||tumor microenvironment:1||tyrosine kinase inhibitor:1||tyrosine kinase inhibitors:1||upper tract urothelial carcinoma:1||upper urinary tract:1||ureteral cancer:1||urethral recurrence:1||uric acid:1||urolithiasis:1||urothelium cancer:1||prostatic neo:1||ARV7:1||AST:1||Abiraterone:1||Abiraterone acetate:1||Acceptance:1||Adjuvant:1||Adjuvant treatment:1||Adverse Effects:1||Anastomosis:1||Androgen antagonists:1||Antineoplastic Agents:1||Apoptosis:1||Apparent diffusion coefficient:1||Approach:1||Atezolizumab:1||B:1||Bcl2:1||Benign prostatic hyperplasia:1||Benign prostatic obstruction:1||Biochemical recurrence:1||Biopsy outcomes:1||Biopsy techniques:1||Biopsynaive patients:1||Bladder cuff method:1||Bladder neoplasm:1||Bladder wall thickening:1||Body Mass Index:1||Calcium oxalate:1||Cancer:1||Carbonic anhydrase IX:1||Carcinoma, Renal cell:1||Cardiovascular Diseases:1||Castrateresistant prostate cancer:1||Castrationnaïve prostate cancer:1||Cell cycle control:1||Childhood brain tumor:1||Circulating tumor DNA:1||Cisplatin:1||Clinical data:1||Clinical decision support system:1||Clinical implication:1||Clinical stage:1||Clinical target volume:1||Combination:1||Competing risk analysis:1||Complication:1||Complications:1||Cyclooxygenase2:1||Cystoscopy:1||Cytology:1||Cytoreductive nephrectomy:1||DNA:1||Database:1||Diagnostic imaging:1||Diffusionweighted MRI:1||Dissection:1||Downgrading:1||EGFR:1||ERG:1||ERK:1||Early death:1||Electronic health records:1||Endometriosis:1||Endoscopy:1||Extraskeletal:1||Factor:1||Functional outcomes:1||Genomic feature:1||Glomerular filtration rate:1||Hemainolevulinate:1||Heng risk criteria:1||High Intensity Focused Ultrasound:1||High grade:1||Highintensity focused ultrasound ablation:1||Histological characteristics:1||Holmium laser enucleation of prostate:1||Hormones:1||IL6:1||IMDC poorrisk:1||Imaging data:1||Insignificant:1||Intraductal carcinoma:1||Kidney function test:1||Kidney neoplasm:1||Kidney neoplasms:1||Kidney transplantation:1||Kidney volume:1||Korean:1||Kv7channel:1||LUTS:1||Laparoscopic:1||Laparoscopic partial nephrectomy:1||Laparoscopic surgery:1||Laser vaporization prostatectomy:1||Learning curve:1||Living donor:1||Locallyadvanced:1||Lymph Node Dissection:1||Lymph Node Metastasis:1||Lymph node excision:1||Lymph node metastases:1||Magnetic Resonance Imaging:1||

STATISTICS: Total View :0; Today View :2,870

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE